MetaCap

Cerus (CERS) vs InfuSystems (INFU)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

InfuSystems (INFU) has outperformed Cerus (CERS) over the past year, gaining 51.7% versus a gain of 14.2%. Over five years, INFU leads with a -15.9% price change compared with -73.5% for CERS. Cerus is the larger company by market cap ($373.6 million vs $287.5 million), about 1.3 times the size.

On valuation, InfuSystems trades at a lower forward P/E (25.6x vs 123.3x for Cerus). InfuSystems converts more of its revenue into profit, with a net margin of 4.6% versus -6.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CERS+14.20%INFU+51.69%
+109%+40%-28%
Nov 21, 20251 yearNov 20, 2026
CERS-74.31%INFU-19.70%
+4%-42%-87%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CERS versus INFU key metrics
MetricCERSINFU
Share price$1.85$14.35
Market cap$373.62M$287.48M
1-day change-2.63%+2.06%
YTD return-10.19%+59.98%
1-year return+14.20%+51.69%
5-year return-73.50%-15.93%
P/E ratio (TTM)—32.61
Forward P/E123.3325.63
EPS (TTM)$-0.04$0.44
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$233.80M$143.44M
Revenue growth (YoY)+16.13%+6.36%
Net income (latest FY)$-15.63M$6.63M
Gross margin—55.98%
Operating margin-3.71%8.31%
Net margin-6.68%4.62%
52-week high$3.47$15.47
52-week low$1.59$7.29
Distance from 52-week high-46.69%-7.24%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+177.30%+28.92%
Average volume2.12M136.60K
Shares outstanding201.95M20.03M
Employees261461
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • INFU has outperformed CERS by 37.5 percentage points over the past year.
  • InfuSystems is more profitable, keeping 4.6 cents of every revenue dollar as net income versus -6.7 cents for Cerus.
  • Cerus grew revenue faster in its latest fiscal year (+16.13% vs +6.36%).

About Cerus

CERS stock →

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety.

Health Care · Medical/Dental Instruments · 261 employees

About InfuSystems

INFU stock →

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps and related products and services in the United States and Canada. It operates through two segments: Patient Services and Device Solutions.

Health Care · Medical/Dental Instruments · 461 employees

CERS vs INFU FAQ

Which is bigger, Cerus or InfuSystems?

Cerus (CERS) is larger, with a market capitalization of $373.62M compared with $287.48M for InfuSystems (INFU).

Which stock has performed better over the past year, CERS or INFU?

INFU returned +51.69% over the past 12 months, compared with +14.20% for CERS (price return, excluding dividends). Past performance does not predict future results.

Are Cerus and InfuSystems in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons